Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2022 Earnings Call Transcript

Roy Buchanan: Okay. Fair enough. All right. And then maybe kind of answer this with the partnering question. But how are you thinking about funding the Phase 3 for 235? Your expense guidance for R&D is going up quite a bit. Are you — does that bake in starting a Phase 3 for 235 possibly start-up for RSV Phase 3s?

Jay Luly: Yes. So, the guidance is our fiscal year guidance that will go out through the quarter in the 9/30 and so again, we’re aiming to have the SPRINT data in the first calendar half. And so any Phase 3 — I mean, we’ve been doing preparations for Phase 3 for quite some time. The CMC drug supply, all the rest, you don’t wait until the last minute. So, we’ve been, if you will, incurring certain Phase 3-related costs right now. And we would expect those to continue up through the quarter of 9/30, and those are included in that number.

Roy Buchanan: Okay, great. Thank you.

Jay Luly: Yes. So, it’s a conservative thing, if there were a partnering change, then obviously, that changes bunches of things. But anyway, so conservatively, we’ve modeled it that way.

Operator: Thank you. I’m showing no further questions in the queue. This concludes our Q&A session. At this time, I would like to turn the conference back over to Jennifer Viera for closing remarks.

Jennifer Viera: Thank you, everyone, for joining us today. If you have additional questions, please feel free to contact us by e-mail or call the office. Have a great evening.

Operator: Thank you. This concludes the conference. You may now disconnect.